The firm said that its nucleic acid amplification test provides viral load measurements of HIV type 1 groups M/N and O, and HIV-2 within 70 minutes
The firm said its new molecular platform, which offers random-access testing, high throughput, and a broad menu has the potential to replace multiple instruments in molecular labs.
Within the diagnostics business, Abbott's core laboratory sales grew 4 percent but its other diagnostic segments were down year over year.
Abbott said that the MDx platform offers a number of initial assays, including tests for HIV-1, HBV, and HCV, among others.
The Polish company recently received 9 million Polish złoty ($2.4 million) from the country's National Center for Research and Development to support its activities.
Alere rapid diagnostics revenues were $548 million in the quarter, driven by infectious disease and cardiometabolic testing product sales.
Abbott said that the next-generation molecular POC assays have also been CLIA waived for use on the Abbott ID NOW instrument, formerly called Alere i.
Molecular diagnostics revenues rose 5 percent driven in part by growth in infectious disease testing, a core area of diagnostic market focus for the firm.
Qiagen's partnership and merger agreement with NeuMoDx may help it compete with high-volume molecular testing vendors such as Abbott, Hologic, and Roche.
Abbott confirmed that the move is a consequence of TwistDx evaluating its operations and strategic direction to align operations and commercial needs.
US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.
In Science this week: almond reference genome, and more.